METHODS OF TREATING PSORIATIC ARTHRITIS USING IL-17 ANTAGONISTS
The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., psoriatic arthritis, which employ a therapeutically effective amount of an Interleukin-17 (IL-17) antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
1 . A method of treating ankylosing spondylitis in a patient, comprising subcutaneously administering about 150 mg secukinumab to the patient every 4 weeks in a composition comprising:
a) 150 mg/mL secukinumab;
b) a sugar;
c) a surfactant selected from polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80; and
d) water;
wherein the composition has a pH of about 5.5 to about 7.4.
2 . The method of claim 1 , wherein the sugar is sucrose, trehalose, raffinose, maltose, sorbitol, or mannitol.
3 . The method of claim 2 , wherein the sugar is sorbitol.
4 . The method of claim 2 , wherein the sugar is trehalose.
5 . The method of claim 2 , wherein the trehalose is at a concentration of about 175 mM to about 300 mM.
6 . The method of claim 1 , wherein the surfactant is at a concentration of about 0.01% to about 0.1%.
7 . The method of claim 5 , wherein the surfactant is polysorbate 80.
8 . The method of claim 1 , wherein the composition further comprises a citrate buffer, a phosphate buffer, a succinate buffer, an acetate buffer, or a Tris buffer.
9 . A method of treating psoriatic arthritis in a patient, comprising subcutaneously administering about 150 mg secukinumab to the patient every 4 weeks in a composition comprising:
a) 150 mg/mL secukinumab;
b) a sugar;
c) a surfactant selected from polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80; and
d) water;
wherein the composition has a pH of about 5.5 to about 7.4.
10 . The method of claim 9 , wherein the sugar is sucrose, trehalose, raffinose, maltose, sorbitol, or mannitol.
11 . The method of claim 10 , wherein the sugar is sorbitol.
12 . The method of claim 11 , wherein the sugar is trehalose.
13 . The method of claim 12 , wherein the trehalose is at a concentration of about 175 mM to about 300 mM.
14 . The method of claim 9 , wherein the surfactant is at a concentration of about 0.01% to about 0.1%.
15 . The method of claim 14 , wherein the surfactant is polysorbate 80.
16 . The method of claim 9 , wherein the composition further comprises a citrate buffer, a phosphate buffer, a succinate buffer, an acetate buffer, or a Tris buffer.
17 . A method of treating ankylosing spondylitis in a patient, comprising subcutaneously administering about 150 mg secukinumab to the patient every 4 weeks in a composition comprising:
a) 150 mg/mL secukinumab;
b) a stabilizer selected from sucrose, mannitol, glycine, arginine, or a combination thereof;
c) a surfactant selected from polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80; and
d) water;
wherein the composition has a pH of about 5.5 to about 7.4; and
wherein the composition is administered every 4 weeks.
18 . The method of claim 17 , wherein the composition comprises at least one sugar.
19 . The method of claim 18 , wherein the at least one sugar is sucrose, trehalose, raffinose, maltose, sorbitol, or mannitol.
20 . The method of claim 19 , wherein the at least one sugar is trehalose.
21 . The method of claim 17 , wherein the surfactant is at a concentration of about 0.01% to about 0.1%.
22 . The method of claim 21 , wherein the surfactant is polysorbate 80.
23 . The method of claim 17 , wherein the composition further comprises a citrate buffer, a phosphate buffer, a succinate buffer, an acetate buffer, or a Tris buffer.
24 . A method of treating psoriatic arthritis in a patient, comprising subcutaneously administering about 150 mg secukinumab to the patient every 4 weeks in a composition comprising:
a) 150 mg/mL secukinumab;
b) a stabilizer selected from sucrose, mannitol, glycine, arginine, or a combination thereof;
c) a surfactant selected from polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80; and
d) water;
wherein the composition has a pH of about 5.5 to about 7.4.
25 . The method of claim 24 , wherein the composition comprises at least one sugar.
26 . The method of claim 25 , wherein the at least one sugar is sucrose, trehalose, raffinose, maltose, sorbitol, or mannitol.
27 . The method of claim 26 , wherein the at least one sugar is trehalose.
28 . The method of claim 24 , wherein the surfactant is at a concentration of about 0.01% to about 0.1%.
29 . The method of claim 28 , wherein the surfactant is polysorbate 80.
30 . The method of claim 24 , wherein the composition further comprises a citrate buffer, a phosphate buffer, a succinate buffer, an acetate buffer, or a Tris buffer.